Tabbara K F, El-Sheikh H F, Islam S M, Hammouda E
The Eye Center and the Eye Foundation for Research in Ophthalmology, Riyadh, Saudi Arabia.
Eur J Ophthalmol. 1999 Oct-Dec;9(4):269-75.
The main purpose of this prospective study was to compare the efficacy, local tolerance, and safety of topical lomefloxacin 0.3% and topical ofloxacin 0.3% in the treatment of acute bacterial conjunctivitis.
Forty patients with acute bacterial conjunctivitis were included in a randomized, prospective, parallel-group study. Twenty patients were assigned to the lomefloxacin group (Okacin, CIBA Vision Ophthalmics) and 20 patients to ofloxacin (Oflox, Allergan). Lomefloxacin 0.3% was given 1 drop every 2 hours during waking hours on the first day then twice daily for one week. Ofloxacin 0.3% eyedrops were given four times daily. All patients underwent eye examination and clinical findings were graded and recorded according to severity of lid hyperemia, lid edema, lid crusting, conjunctival edema and discharge, bulbar conjunctival hyperemia, palpebral conjunctival hyperemia, corneal edema, and ocular discomfort. The score for each clinical sign was recorded before and after treatment. The mean cumulative sum score (CSS) was obtained by adding the scores for signs and symptoms. All conjunctival swabs were cultured and tested for sensitivity. Patients with confirmed bacterial conjunctivitis were included.
There were 10 male and 10 female patients in each group. The age range was from 1 to 78 years, and the mean age was 35 years in the lomefloxacin group. In the ofloxacin group the age range was from 1 to 70 years, and the mean age was 26 years. There was no significant difference between the two groups in relation to age or sex. The causative organisms were Staphylococcus epidermidis in 16 cases (36%), alpha-hemolytic Streptococci in 9 (20%), Haemophilus spp. 6 (13%), Staphylococcus aureus 5 (11%), Streptococcus pneumoniae 4 (9%), Pseudomonas aeruginosa 3 (7%), and other 2 (4%). The mean CSS for conjunctivitis was 12.1 before therapy in the lomefloxacin group and 12.7 in the ofloxacin group. On the 7th day of therapy, the mean CSS was 0.7 in the lomefloxacin group, and 1.6 for ofloxacin. All patients showed improvement, but a total of 18 out of 20 (88%) in the lomefloxacin group showed complete resolution compared to 15 (75%) in the ofloxacin group. The difference was not statistically significant (p = 0.08). Tolerance was excellent in both groups, and no side effects were reported. A burning sensation was noted by two patients, one in each group.
Lomefloxacin and ofloxacin were equally effective and safe in the treatment of acute bacterial conjunctivitis.
本前瞻性研究的主要目的是比较0.3%的洛美沙星滴眼液与0.3%的氧氟沙星滴眼液治疗急性细菌性结膜炎的疗效、局部耐受性及安全性。
40例急性细菌性结膜炎患者纳入一项随机、前瞻性、平行组研究。20例患者被分配至洛美沙星组（奥卡星，CIBA Vision眼科公司），20例患者被分配至氧氟沙星组（氧氟沙星，Allergan公司）。0.3%的洛美沙星在第一天清醒时每2小时滴1滴，然后每日2次，共1周。0.3%的氧氟沙星滴眼液每日滴4次。所有患者均接受眼部检查，并根据睑结膜充血、睑水肿、睑结痂、结膜水肿及分泌物、球结膜充血、睑结膜充血、角膜水肿和眼部不适的严重程度对临床症状进行分级和记录。在治疗前后记录每个临床症状的评分。通过将症状和体征的评分相加得到平均累积总分（CSS）。所有结膜拭子均进行培养并检测敏感性。纳入确诊为细菌性结膜炎的患者。
每组各有10例男性和10例女性患者。年龄范围为1至78岁，洛美沙星组的平均年龄为35岁。在氧氟沙星组，年龄范围为1至70岁，平均年龄为26岁。两组在年龄或性别方面无显著差异。致病微生物为表皮葡萄球菌16例（36%）、α-溶血性链球菌9例（20%）、嗜血杆菌属6例（13%）、金黄色葡萄球菌5例（11%）、肺炎链球菌4例（9%）、铜绿假单胞菌3例（7%），其他2例（4%）。洛美沙星组结膜炎的平均CSS在治疗前为12.1，氧氟沙星组为12.7。在治疗第7天，洛美沙星组的平均CSS为0.7，氧氟沙星组为1.6。所有患者均有改善，但洛美沙星组20例中有18例（88%）完全治愈，而氧氟沙星组为15例（75%）。差异无统计学意义（p = 0.08）。两组的耐受性均良好，未报告有副作用。每组各有1例患者出现烧灼感。
洛美沙星和氧氟沙星在治疗急性细菌性结膜炎方面疗效和安全性相当。
